<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Biosci Rep</journal-id><journal-id journal-id-type="iso-abbrev">Biosci. Rep</journal-id><journal-id journal-id-type="publisher-id">bsr</journal-id><journal-title-group><journal-title>Bioscience Reports</journal-title></journal-title-group><issn pub-type="ppub">0144-8463</issn><issn pub-type="epub">1573-4935</issn><publisher><publisher-name>Portland Press Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7199450</article-id><article-id pub-id-type="pmid">32293004</article-id><article-id pub-id-type="doi">10.1042/BSR20194237</article-id><article-id pub-id-type="publisher-id">BSR20194237</article-id><article-categories><subj-group subj-group-type="heading"><subject>Cancer</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Migration, Adhesion &#x00026; Morphology</subject></subj-group><subj-group subj-group-type="heading"><subject>Diagnostics &#x00026; Biomarkers</subject></subj-group><subj-group subj-group-type="toc-heading"><subject>Research Articles</subject></subj-group></article-categories><title-group><article-title>Circular RNA hsa_circ_0072309 inhibits non-small cell lung cancer progression by sponging miR-580-3p</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Pang</surname><given-names>Wenguang</given-names></name><xref ref-type="aff" rid="AFF1"/><xref ref-type="aff" rid="AFF2"/></contrib><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Fengliu</given-names></name><xref ref-type="aff" rid="AFF3"/></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Xin</given-names></name><xref ref-type="aff" rid="AFF4"/></contrib><contrib contrib-type="author"><name><surname>Ye</surname><given-names>Min</given-names></name><xref ref-type="aff" rid="AFF2"/></contrib><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Yanming</given-names></name><xref ref-type="aff" rid="AFF3"/></contrib><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Xiufang</given-names></name><xref ref-type="aff" rid="AFF5"/></contrib><contrib contrib-type="author"><name><surname>Pang</surname><given-names>Jingzhuo</given-names></name><xref ref-type="aff" rid="AFF2"/></contrib><contrib contrib-type="author"><name><surname>Cai</surname><given-names>Chengjie</given-names></name><xref ref-type="aff" rid="AFF2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-1515-2288</contrib-id><name><surname>Wang</surname><given-names>Zheng</given-names></name><email>qwer112123@126.com</email><xref ref-type="aff" rid="AFF6"/><xref ref-type="corresp" rid="COR1"/></contrib></contrib-group><aff id="AFF1"><label>1</label>Department of Thoracic Surgery, The First Affiliated Hospital of Jinan University, Guangzhou 510630, China</aff><aff id="AFF2"><label>2</label>Department of Thoracic Surgery, Jiangmen Central Hospital, Jiangmen 529030, China</aff><aff id="AFF3"><label>3</label>Department of Respiration Medicine, Jiangmen Central Hospital, Jiangmen 529030, China</aff><aff id="AFF4"><label>4</label>Clinical Experimental Center (Clinical Biobanks), Jiangmen Central Hospital, Jiangmen 529030, China</aff><aff id="AFF5"><label>5</label>Department of Pathology, Jiangmen Central Hospital, Jiangmen 529030, China</aff><aff id="AFF6"><label>6</label>Department of Thoracic Surgery, The 2nd Clinical Medical College of Jinan University, Shenzhen 518020, China</aff><author-notes><corresp id="COR1"><bold>Correspondence:</bold> Zheng Wang (<email>qwer112123@126.com</email>)</corresp></author-notes><pub-date pub-type="collection"><day>29</day><month>5</month><year>2020</year></pub-date><pub-date pub-type="epub" iso-8601-date="2020-05-04"><day>04</day><month>5</month><year>2020</year></pub-date><volume>40</volume><issue>5</issue><elocation-id>BSR20194237</elocation-id><history><date date-type="received"><day>07</day><month>12</month><year>2019</year></date><date date-type="rev-recd"><day>24</day><month>3</month><year>2020</year></date><date date-type="accepted"><day>31</day><month>3</month><year>2020</year></date><date date-type="accepted-manuscript"><day>15</day><month>4</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 The Author(s).</copyright-statement><copyright-year>2020</copyright-year><license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).</license-p></license></permissions><self-uri xlink:href="bsr-40-bsr20194237.pdf"/><abstract><title>Abstract</title><p><bold>Objective:</bold> Non-small cell lung cancer (NSCLC) continues to top the list of cancer mortalities worldwide. Early diagnosis and therapeutic interventions targeting NSCLC is becoming the world&#x02019;s significant challenge. Circular RNAs (circRNAs) are emerging as a group of potential cancer biomarkers.</p><p><bold>Materials and methods:</bold> Quantitative real-time PCR (qRT-PCR) was employed to examine the expression of circ_0072309 in NSCLC tissues and cell lines. Cell counting kit 8 (CCK-8), wound healing and Transwell assays were used to analyze cell proliferation, migration and invasion in A549 and H1299 cells. The relationship between circ_0072309 and miR-580-3 was analyzed by Luciferase reporter and RNA pull down assays.</p><p><bold>Results:</bold> We screened circ_0072309 from Gene Expression Omnibus and found that circ_0072309 was lowly expressed in NSCLC tissues and cell lines. The transfection of circ_0072309-overexpressing vector significantly suppressed the cell proliferation, migration and invasion in A549 and H1299 cells. We predicted that miR-580-3p is a target of circ_0072309 by using publicly available bioinformatic algorithms Circinteractome tool and confirmed that circ_0072309 directly bound to miR-580-3p. Furthermore, the addition of miR-580-3p mitigated the blockage of cell proliferation, migration and invasion induced by circ_0072309.</p><p><bold>Conclusions:</bold> These data showed that circ_0072309 inhibits the progression of NSCLC progression via blocking the expression of miR-580-3p. These findings revealed the anti-tumor role of circ_0072309 during the development of NSCLC and provided a novel diagnostic biomarker and potential therapy for NSCLC.</p></abstract><kwd-group><kwd>hsa_circ_0072309</kwd><kwd>miR-580-3p</kwd><kwd>non-small cell lung cancer</kwd></kwd-group><counts><page-count count="10"/></counts></article-meta></front><body><sec sec-type="intro" id="sec1"><title>Introduction</title><p>Lung cancer is one of the most commonly found carcinoma type and is an aggressive tumor with high incidence and mortality rate worldwide [<xref rid="B1" ref-type="bibr">1</xref>]. Non-small cell lung cancer (NSCLC) accounts for 80&#x02013;85% of lung cancer diagnoses and is the major cause of lung cancer-associated mortality due to late-stage detection [<xref rid="B2" ref-type="bibr">2</xref>]. Despite advances in clinical and experimental oncology have been made in recent years, the 5-year overall survival rate of NSCLC is still limited [<xref rid="B3" ref-type="bibr">3</xref>]. Thus, to explore the molecular mechanisms of NSCLC and to identify effective biomarkers is essential for NSCLC early diagnosis and treatments.</p><p>Circular RNAs (circRNAs) are a new class of noncoding RNA molecules with the length of at least a few hundred nucleotides lacking 5&#x02032; caps or 3&#x02032; poly-A tails [<xref rid="B4" ref-type="bibr">4</xref>]. CircRNAs are reported to closely associate with the progression of a large number of cancers [<xref rid="B5" ref-type="bibr">5</xref>]. Aberrant regulation of circRNAs has been noted in gliomas [<xref rid="B6" ref-type="bibr">6</xref>], renal cell carcinomas [<xref rid="B7" ref-type="bibr">7</xref>] and other human malignancies [<xref rid="B8" ref-type="bibr">8</xref>]. With the development of high-throughput sequencing and bioinformatics analysis, increasing numbers of novel circRNAs have been identified to be potential cancer prognostic biomarkers [<xref rid="B9" ref-type="bibr">9</xref>]. CircRNA has_circ_0072309 was identified to be located on chromosome 5 between the base sites 38523520 and 38530768 [<xref rid="B10" ref-type="bibr">10</xref>]. Some reports showed that has_circ_0072309 was lowly expressed in breast cancer [<xref rid="B11" ref-type="bibr">11</xref>,<xref rid="B12" ref-type="bibr">12</xref>], human intracranial aneurysms [<xref rid="B10" ref-type="bibr">10</xref>] and renal carcinoma [<xref rid="B13" ref-type="bibr">13</xref>]. However, the function of has_circ_0072309 in the progression of NSCLC remains elusive.</p><p>In the present study, we screened the circ_0072309 from GSE112214 dataset. Quantitative real-time PCR (qRT-PCR) results showed that circ_0072309 was down-regulated in NSCLC tissues and cell lines. The overexpression of circ_0072309 significantly blocked the cell proliferation, migration and invasion in A549 and H1299 cells. Luciferase reporter and RNA pull down assays indicated that circ_0072309 directly bound to miR-580-3p. The blockage of cell proliferation, migration and invasion induced by circ_0072309 was mitigated by miR-580-3p mimic. Taken together, our study indicated that circ_0072309 blocks NSCLC tumor progression by sponging miR-580-3p. These findings provided a novel biomarker and potential treatment strategy for NSCLC diagnosis and clinical treatment.</p></sec><sec sec-type="materials|methods" id="sec2"><title>Materials and methods</title><sec id="sec2-1"><title>Clinical samples</title><p>The clinical specimens including 30 pairs of NSCLC tissues and adjacent normal tissues were isolated from patients who underwent surgery between 2016 and 2018 at the Department of Thoracic Surgery, The 2nd Clinical Medical College of Jinan University. Patients did not receive any preoperative therapy, including radiotherapy and chemotherapy before surgery. The pathological diagnosis of tissue samples were performed by two pathologists according to WHO grade criteria. All tissues were isolated and immediately transferred into liquid nitrogen for follow-up experiments. All patients have signed the informed consents prior to their participation in the study. The study was reviewed and approved by the Ethics Committee of The 2nd Clinical Medical College of Jinan University.</p></sec><sec id="sec2-2"><title>Cell culture and transfection</title><p>Normal human bronchial epithelial cell line (HBE, BNCC338600) and four human NSCLC cells lines including CALU3 (BNCC338499), H125 (BNCC100831), A549 (BNCC100258) and H1299 (BNCC100268) were purchased from BeNa Culture Collection (Beijing, China). Cells were maintained in Roswell Park Memorial Institute-1640 (RPMI-1640, Invitrogen, Thermo Fisher Scientific, Waltham, MA, U.S.A.) containing 10% fetal bovine serum (FBS, Gibco, Grand Island, NY, U.S.A.) under the atmosphere containing 5% CO<sub>2</sub> at 37&#x000b0;C.</p><p>Circ_0072309 was inserted into the pcDNA3.1 vector (pcDNA3.1-circ_0072309) to construct circ_0072309-overexpressing vector. For circ_0072309 overexpression, cells were transfected with pcDNA3.1-circ_0072309 (circ_0072309) or empty pcDNA3.1 (Vector). The miR-580-3p mimic and miR-NC were purchased from GenePharma (Shanghai, China). The transfections were performed using Lipofectamine 3000 (Invitrogen, Carlsbad, CA, U.S.A.) according to the manufacturer&#x02019;s instructions. After 48 h, cells were collected for follow-up experiments.</p></sec><sec id="sec2-3"><title>qRT-PCR</title><p>Total RNA was extracted from tissues or cells by using TRIzol (Invitrogen, Carlsbad, CA, U.S.A.) according to the manufacturer&#x02019;s protocol. The cDNA was synthesized with First Strand cDNA Synthesis Kit (TaKaRa, Dalian, Liaoning, China). SYBR Premix ExTaq II Kit (TaKaRa, Dalian, Liaoning, China) was used to determine the expression level of target genes through the StepOnePlus system (Applied Biosystems, CA, U.S.A.) in line with the manufacturer&#x02019;s protocol, and the 2<sup>&#x02212;&#x00394;&#x00394;<italic>C</italic><sub>T</sub></sup> method was adopted to calculate the relative expression of circ_0072309 and miR-580-3p. The primers for qRT-PCR were listed as follows: circ_0072309 forward primer (F): 5&#x02032;- ggtcccgttcttgttagact-3&#x02032;, reverse primer (R): 5&#x02032;-gatggtcgtttcaaacatac-3&#x02032;; miR-580-3p F: 5&#x02032;-gccgagttgagaatgatgaa-3&#x02032;, R: 5&#x02032;-tggtgtcgtggagtcgg-3&#x02032;; GAPDH F: 5&#x02032;-gggaaactgtggcgtgat-3&#x02032;, GAPDH R: 5&#x02032;-gagtgggtgtcgctgttga-3&#x02032;; U6 F: 5&#x02032;-ctcgcttcggcagcaca-3&#x02032;, R: 5&#x02032;-aacgcttcacgaatttgcgt-3&#x02032;.</p></sec><sec id="sec2-4"><title>Cell viability assay</title><p>Cell viability was determined by using cell counting kit 8 (CCK-8, Donjindo, Kumamoto, Japan). Cells were seeded into a 96-well plate at the density of 2 &#x000d7; 10<sup>3</sup> cells/well. After 0, 24, 48, 72 and 96 h, cells were incubated with 10 &#x003bc;l of CCK-8 reagent and incubated at 37&#x000b0;C for 2 h. Finally, the optical density was measured using EnSpire&#x02122; 2300 Multilabel Reader (PerkinElmer Inc., Waltham, MA, U.S.A.) at the wavelength of 450 nm. The experiment was repeated three times independently.</p></sec><sec id="sec2-5"><title>Wound-healing assay</title><p>Cells were seeded into a six-well plate until they reached 70&#x02013;80% confluence as a monolayer. The cell monolayer was gently and slowly scratched with sterile plastic 20 &#x003bc;l micropipette tips across the center of the attached cells. After 0 and 24 h, images were captured using a light microscope (Olympus IX81, Tokyo, Japan). The migration distance of the cells was measured using Image Pro-Plus version 6.0 (Media Cybernetics Inc., Rockville, MD, U.S.A.). The experiment was repeated three times independently.</p></sec><sec id="sec2-6"><title>Transwell assay</title><p>Matrigel-coated (BD Biosciences, Franklin Lakes, NJ, U.S.A.) Transwell inserts (Costar, Manassas, VA, U.S.A.) were used to measure the invasive capacity of cells. The inserts were coated with 50 &#x003bc;l of 1 mg/ml Matrigel according to the manufacturer&#x02019;s protocol. A total of 2 &#x000d7; 10<sup>5</sup> cells in 200 &#x003bc;l of Dulbecco&#x02019;s modified Eagle&#x02019;s medium (DMEM) without serum were plated to the upper chamber. DMEM with 10% FBS was added to the lower compartment as a chemoattractant. After 24-h incubation, cells invading the lower surface of the membrane were fixed with cold methanol-glacial acetic acid and stained with 1% Crystal Violet for 15 min at room temperature. For each membrane, five fields (up, down, center, left and right, &#x000d7;200) were selected for cell counting and photographed under the microscope (Canon, Tokyo, Japan). Transwell assays were performed with two technical replicates and three independent biological replicates.</p></sec><sec id="sec2-7"><title>Biotinylated-RNA pull down</title><p>Biotinylated miR-580-3p probe was synthesized by GenePharma (Shanghai, China). Cells were seeded into six-well plates and transfected with bio-miR-580-3p or bio-miR NC at a final concentration of 20 nM for 24 h. The probe was incubated with M280 streptavidin dynabeads (Life Technologies Inc., Rockville, Maryland, U.S.A.) at 25&#x000b0;C for 2 h to generate probe-coated beads. The biotin&#x02013;conjugated RNA complex was pulled down after incubation of the cell lysates with streptavidin-coated magnetic beads and extracted with TRIzol reagent. The level of circ_0072309 in bound fractions was evaluated by qRT-PCR analysis.</p></sec><sec id="sec2-8"><title>Luciferase report assay</title><p>The luciferase reporter plasmid (Luc) was purchased from OBiO Technology (Shanghai, China). Sequences containing potential wild-type or mutant binding sites for miRNAs in circ_0072309 were cloned downstream of the luciferase gene promoter (Luc-circ_0072309 or Luc-circ_0072309-mutant). Cells were seeded into 24-well plates at the concentration of 5 &#x000d7; 10<sup>4</sup> cells/well and co-transfected with Luc-circ_0072309 or Luc-circ_0072309-mutant, with miR-580-3p mimic or miRNA NC. After 48 h, cells were extracted and the Dual Luciferase Reporter Assay was measured using the dual-luciferase reporter assay system (Promega, Madison, WI, U.S.A.) by normalizing the firefly luminescence to <italic>Renilla</italic> luminescence. The experiment was repeated three times independently.</p></sec><sec id="sec2-9"><title>Statistical analysis</title><p>Data were presented as the mean &#x000b1; standard deviation. Statistical analysis was carried out with IBM SPSS version 18.0 (SPSS, Inc., Chicago, IL, U.S.A.). Difference between two groups was analyzed using Student&#x02019;s <italic>t</italic> test and the analysis of multiple groups was carried out by using one-way analysis of variance followed by Dunnett&#x02019;s post-hoc analysis. *<italic>P</italic>&#x0003c;0.05 was considered to indicate a statistically significant difference. All experiments in the present study were repeated three times at least.</p></sec></sec><sec sec-type="results" id="sec3"><title>Results</title><sec id="sec3-1"><title>Circ_0072309 is down-regulated in NSCLC tissues and cell lines</title><p>We analyzed the microarray data (GSE112214 containing three pairs of NSCLC tissues and matched non-tumor tissues) from the GEO database (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/gds/">http://www.ncbi.nlm.nih.gov/gds/</ext-link>). The criteria for selection of differentially expressed circRNAs were |log2FC (fold change)| &#x02265; 1 and <italic>P</italic>&#x0003c;0.05. The top 15 up- and 15 down-expressed circRNAs were displayed in <xref ref-type="fig" rid="F1">Figure 1</xref>A by using heatmaps. We found that the expression of circ_0072309 in NSCLC tissues was the lowest. In addition, in GSE112214 dataset, the expression of circ_0072309 in three NSCLC tissues was lower than that in matched non-tumor tissues (<xref ref-type="fig" rid="F1">Figure 1</xref>B). We further collected 30 patients and confirmed the expression of circ_0072309 in NSCLC tissues and non-tumor tissues in <xref ref-type="fig" rid="F1">Figure 1</xref>C. Similar results observed that circ_0072309 was down-regulated in patient-derived NSCLC tumor specimens versus adjacent healthy lung tissues. We extended our analysis from NSCLC tumor tissues to NSCLC cell lines. Compared with HBE, the expression of circ_0072309 in NSCLC cell lines (CALU3, H125, A549 and H1299) was significantly blocked (<xref ref-type="fig" rid="F1">Figure 1</xref>D). Among the four NSCLC cell lines, circ_0072309 expression in A549 and H1299 cells was lower than that in CALU3 and H125 cells. We selected A549 and H1299 cells for subsequent cir_0072309 overexpression experiments. Taken together, these data indicated that circ_0072309 is poorly expressed in NSCLC tissues and cell lines.</p><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><title>circ_0072309 is poorly expressed in NSCLC tissues and cell lines</title><p>(<bold>A</bold>) The heatmaps displayed the top 15 up- and down-expressed circRNAs between NSCLC and adjacent non-tumor tissues in GSE112214 based on the criteria of |log2FC| &#x0003e; 1 and <italic>P</italic>&#x0003c;0.05. Red in the two plots denoted up-regulation and blue stood for down-regulation. (<bold>B</bold>) circ_0072309 was lowly expressed in three NSCLC tissues in comparison with adjacent non-tumor tissues in GSE112214 dataset. (<bold>C</bold>) circ_0072309 was down-regulated in patient-derived NSCLC tumor specimens versus adjacent healthy lung tissues (<italic>n</italic>=30). (<bold>D</bold>) The expression of circ_0072309 was blocked in NSCLC cell lines. Total RNA was extracted from tissues or cells and qRT-PCR was performed to detect the expression of targets. **<italic>P</italic>&#x0003c;0.01.</p></caption><graphic xlink:href="bsr-40-bsr20194237-g1"/></fig></sec><sec id="sec3-2"><title>circ_0072309 inhibits cell proliferation, migration and invasion in A549 and H1299 cells</title><p>To explore the role of circ_0072309 in NSCLC carcinogenesis, we transfected A549 and H1299 cells with pcDNA3.1-circ_0072309 and empty pcDNA3.1 (Vector), and then performed CCK-8, wound-healing and Transwell assays. qRT-PCR was employed to confirm the transfection efficiency. In <xref ref-type="fig" rid="F2">Figure 2</xref>A, compared with Vector group, the transfection of pcDNA3.1-circ_0072309 significantly enhanced the expression of circ_0072309, suggesting that pcDNA3.1-circ_0072309 was successfully overexpressed in A549 and H1299 cells. In <xref ref-type="fig" rid="F2">Figure 2</xref>B, CCK-8 assay results showed that circ_0072309 overexpression significantly inhibited A549 and H1299 cell viability compared with that in Vector-transfected cells. These data showed that circ_0072309 inhibited cell proliferation in NSCLC cells.</p><fig id="F2" orientation="portrait" position="float"><label>Figure 2</label><caption><title>The overexpression of circ_0072309 significantly blocks cell proliferation, migration and invasion</title><p>(<bold>A</bold>) The transfection of pcDNA3.1-circ_0072309 up-regulated the expression of circ_0072309 determined by qRT-PCR in A549 and H1299 cells. (<bold>B</bold>&#x02013;<bold>D</bold>) The overexpression of circ_0072309 blocked the cell viability, migration and invasion determined by CCK-8, wound healing and Transwell assays in A549 and H1299 cells. Cells were transfected with pcDNA3.1-circ_0072309 (circ_0072309) or pcDNA3.1 (vector). Total RNA was extracted for qRT-PCR and cells were collected for CCK-8, wound healing and Transwell assays. **<italic>P</italic>&#x0003c;0.01.</p></caption><graphic xlink:href="bsr-40-bsr20194237-g2"/></fig><p>We further examined the effect of circ_0072309 on migration and invasion capabilities through wound healing and Transwell assays. In <xref ref-type="fig" rid="F2">Figure 2</xref>C, compared with the Vector group, cells transfected with pcDNA3.1-circ_0072309 showed a wider wound area at 24 h after cell propagation. Similarly, the overexpression of circ_0072309 significantly decreased the number of invasive cells compared with Vector group in <xref ref-type="fig" rid="F2">Figure 2</xref>D. These results showed that circ_0072309 prevented cell migration and invasion in NSCLC cells. Taken together, the overexpression of circ_0072309 significantly blocks cell proliferation, migration and invasion in A549 and H1299 cells.</p></sec><sec id="sec3-3"><title>circ_0072309 serves as a sponge for miR-580-3p</title><p>To determine the mechanism of circ_0072309 functioning in NSCLC, we first analyzed the subcellular location of circ_0072309 by qRT-PCR and found that circ_0072309 was mainly located in the cytoplasm shown in <xref ref-type="fig" rid="F3">Figure 3</xref>A. Many circRNAs may act as competitive endogenous RNAs and modulators of miRNA activity by competing for miRNA-binding sites [<xref rid="B14" ref-type="bibr">14</xref>]. Based on the prediction provided by publicly available bioinformatics algorithms Circinteractome tool (<ext-link ext-link-type="uri" xlink:href="https://circinteractome.nia.nih.gov">https://circinteractome.nia.nih.gov</ext-link>), we fortunately found a putative miR-580-3p binding site on the circ_0072309 sequence. To explore the relationship between circ_0072309 and miR-580-3p, we first constructed a wild-type (circ_0072309 wt) or a mutant (circ_0072309 mut) luciferase reporter plasmid (<xref ref-type="fig" rid="F3">Figure 3</xref>B). Cells co-transfected with circ_0072309 wt and miR-580-3p mimic significantly decreased the luciferase signal in comparison with cells transfected with circ_0072309 wt and miR NC (<xref ref-type="fig" rid="F3">Figure 3</xref>C). However, no significant difference was detected in the luciferase signal intensity of circ_0072309 mut between the miR-580-3p mimic and miR NC (<italic>P</italic>&#x0003e;0.05). These findings indicated that circ_0072309 bound to miR-580-3p. We further performed an RNA pull down using a biotin-labeled miR-580-3p probe. In <xref ref-type="fig" rid="F3">Figure 3</xref>D, circ_0072309 was enriched within the miR-580-3p probe pull-down RNA complex in comparison with miR NC. These data suggested that circ_0072309 directly interacted with miR-580-3p. In A549 and H1299 cells, the overexpression of circ_0072309 significantly blocked the expression of miR-580-3p (<xref ref-type="fig" rid="F3">Figure 3</xref>E), indicating that the negative relationship between circ_0072309 and miR-580-3p. Taken together, these data indicated that circ_0072309 serves as a sponge for miR-580-3p in A549 and H1299 cells.</p><fig id="F3" orientation="portrait" position="float"><label>Figure 3</label><caption><title>circ_0072309 directly binds to miR-580-3p</title><p>(<bold>A</bold>) circ_0072309 was localized at cytoplasm determined by qRT-PCR. (<bold>B</bold>) A wild-type (circ_0072309 wt) or a mutant (circ_0072309 mut) luciferase reporter plasmid was constructed based on the prediction by Circinteractome tool (<ext-link ext-link-type="uri" xlink:href="https://circinteractome.nia.nih.gov">https://circinteractome.nia.nih.gov</ext-link>). (<bold>C</bold>) Luciferase report assay was performed with circ_0072309 wt or circ_0072309 mut and miR-580-3p mimic. (<bold>D</bold>) RNA pull down was carried out with biotin-labeled miR-580-3p probe. (<bold>E</bold>) The overexpression of circ_0072309 significantly blocked the expression of miR-580-3p. (<bold>F</bold>) TCGA data showed that miR-580-3p was highly expressed in NSCLC tissues. (<bold>G</bold>) miR-580-3p was highly expressed in patient-derived NSCLC tumor specimens (<italic>n</italic>=30). **<italic>P</italic>&#x0003c;0.01. Abbreviation: TCGA, The Cancer Genome Atlas.</p></caption><graphic xlink:href="bsr-40-bsr20194237-g3"/></fig></sec><sec id="sec3-4"><title>circ_0072309 blocks cell proliferation, migration and invasion through miR-580-3p in NSCLC cells</title><p>After confirming the interaction between circ_0072309 and miR-580-3p, we further examined whether the anti-tumor function of circ_0072309 is attributed to its repression of miR-580-3p. We downloaded the data from The Cancer Genome Atlas (TCGA, <ext-link ext-link-type="uri" xlink:href="https://cancergenome.nih.gov/">https://cancergenome.nih.gov/</ext-link>). A total of 565 samples were included in the present study, containing 519 NSCLC samples and 46 matched non-tumor tissues. The expression of miR-580-3p in NSCLC tissues were significantly up-regulated than those in non-tumor tissues (<xref ref-type="fig" rid="F3">Figure 3</xref>F). The similar trend was found in the patient-derived NSCLC tumor specimens versus adjacent healthy lung tissue (<xref ref-type="fig" rid="F3">Figure 3</xref>G). These data suggested that miR-580-3p might exert as an oncogene in NSCLC progression. We transfected miR-580-3p mimic in circ_0072309-overexpressing cells and performed functional assays in <xref ref-type="fig" rid="F4">Figure 4</xref>A. CCK-8 assay results showed that the overexpression of circ_0072309 significantly blocked cell viability, however, the addition of miR-580-3p mimic rescued the blockage of cell viability (<xref ref-type="fig" rid="F4">Figure 4</xref>B). Similar results were observed in wound healing and Transwell assays. The administration of miR-580-3p mimic mitigated the blockage of the migration and invasion induced by circ_0072309 (<xref ref-type="fig" rid="F4">Figure 4</xref>C,D). These data showed that the transfection of miR-580-3p mimic into circ_0072309 overexpressing cells rescued proliferation, migration and invasion defects, suggesting that circ_0072309 inhibited NSCLC progression through blocking the function of miR-580-3p.</p><fig id="F4" orientation="portrait" position="float"><label>Figure 4</label><caption><title>The addition of miR-580-3p mimic rescues the blockage of cell proliferation, migration and invasion caused by circ_0072309</title><p>(<bold>A</bold>) The transfection of miR-580-3p mimic promoted the expression of miR-580-3p blocked by circ_0072309. (<bold>B&#x02013;D</bold>) The addition of miR-580-3p mimic rescues the inhibition of cell proliferation, migration and invasion caused by circ_0072309 overexpression determined by CCK-8, wound healing and Transwell assays. Cells were randomly divided into three groups: Vector, circ_0072309 and circ_0072309+miR-580-3p mimic. Cells in circ_0072309 or circ_0072309+miR-580-3p mimic were transfected with pcDNA3.1-circ_0072309 or pcDNA3.1-circ_0072309+miR-580-3p mimic for 48 h, respectively. Vector group was transfected with pcDNA3.1. Cells were collected for CCK-8, wound healing and Transwell assays. **<italic>P</italic>&#x0003c;0.01.</p></caption><graphic xlink:href="bsr-40-bsr20194237-g4"/></fig></sec></sec><sec sec-type="discussion" id="sec4"><title>Discussion</title><p>Lung cancer is an aggressive tumor with high incidence and mortality rate [<xref rid="B15" ref-type="bibr">15</xref>]. NSCLC is responsible for poor survival of a majority of lung cancer patients [<xref rid="B16" ref-type="bibr">16</xref>]. Due to non-specific symptoms and no effectual diagnostic tests, approximately 70% of NSCLC are diagnosed at an advanced stage [<xref rid="B17" ref-type="bibr">17</xref>]. Non-invasive prognostic biomarkers are needed for the diagnosis of the advanced NSCLC patients with different histological types [<xref rid="B18" ref-type="bibr">18</xref>]. With the advance in the study of the molecular basis about lung cancer progression, targeted therapies have been used for NSCLC treatment [<xref rid="B19" ref-type="bibr">19</xref>].</p><p>CircRNAs are a group of non-coding RNAs with a stable closed-loop structure which prevents them from decomposing by the enzymes [<xref rid="B20" ref-type="bibr">20</xref>]. Increasing evidence indicated that circRNAs are closely associated with the progression of NSCLC [<xref rid="B21" ref-type="bibr">21</xref>]. For example, inhibition of circRNA VANGL1 suppresses the progression of bladder cancer [<xref rid="B22" ref-type="bibr">22</xref>]. Circ_000984 promotes cell proliferation and metastasis in NSCLC by modulating Wnt/&#x003b2;-catenin pathway [<xref rid="B23" ref-type="bibr">23</xref>]. CircRNA circFOXO3 promotes the prostate cancer progression [<xref rid="B24" ref-type="bibr">24</xref>]. The down-regulation of circRNA ciRS-7 [<xref rid="B25" ref-type="bibr">25</xref>] or circ_0067934 [<xref rid="B26" ref-type="bibr">26</xref>] blocks cell proliferation, migration and invasion of NSCLC cells. In our study, we found circ_0072309 was down-regulated in NSCLC tissues and cells, and the overexpression of circ_0072309 significantly blocked cell proliferation, migration and invasion, suggesting that circ_0072309 serves as a tumor suppressor in NSCLC. These data provided new evidence about the role of circRNA during the progression of cancers and provided a new biomarker for NSCLC diagnosis and therapy.</p><p>Emerging evidence showed that circRNAs were involved in the progression of tumors by acting as miRNA sponges in the cytoplasm [<xref rid="B27" ref-type="bibr">27</xref>], thereby regulating gene expression in transcriptional and post-transcriptional manners [<xref rid="B28" ref-type="bibr">28</xref>]. Previous study showed that circ_0072309 inhibits the proliferation and invasion in breast cancer via targeting miR-492 [<xref rid="B12" ref-type="bibr">12</xref>]. In human intracranial aneurysms, circ_0072309 acts as a ceRNA to affect discoid domain receptor 2 and systemic amino acid transporter 2 through miR-519e-5p and miR-516b-5p [<xref rid="B10" ref-type="bibr">10</xref>]. In renal carcinoma, circ_0072309 exerts anti-tumor roles by sponging miR-100 [<xref rid="B13" ref-type="bibr">13</xref>]. In our present study, we predicted that miR-580-3p is a target of circ_0072309 by bioinformatics analysis and employed luciferase report assay and RNA pull down methods to confirm that circ_0072309 directly binds to miR-580-3p. These data provided new evidence that miR-380-3p is a new target of circ_0072309 in NSCLC.</p><p>TWIST1 contributes to metastasis by promoting epithelial&#x02013;mesenchymal transition and is misregulated in various cancers [<xref rid="B29" ref-type="bibr">29</xref>]. In breast cancer, miR-580 is able to target the 3&#x02032;UTR of TWIST1 and overexpression of miR-580 inhibits cell motility [<xref rid="B30" ref-type="bibr">30</xref>]. It is reported that overexpression of miR-580 inhibits tumor growth in osteosaroma cell and the expression levels of miR-580 decreased with advanced tumor grade in glioma [<xref rid="B31" ref-type="bibr">31</xref>]. In neuroblastoma, serum miR-580 level is significantly up-regulated, which can be a potential prognostic marker [<xref rid="B32" ref-type="bibr">32</xref>]. miR-580 is identified to be positively associated with the pathogenesis and development of melanoma [<xref rid="B33" ref-type="bibr">33</xref>]. Although the role of miR-580 is reported, unfortunately, the knowledge of the function of miR-580-3p is very limited, especially their contribution to cancer progression. In our study, we found that miR-580-3p was highly expressed in NSCLC tissues, suggesting miR-580-3p was involved in the progression of NSCLC. In addition, the administration of miR-580-3p rescued the blockage of cell proliferation, migration and invasion induced by circ_0072309. These results further confirmed the role of circ_0072309 and miR-580-3p and revealed the mechanism that circ_0072309 inhibits the development of NSCLC by sponging miR-580-3p.</p><p>In summary, circ_0072309 blocks the progression of NSCLC by directly binding to miR-580-3p. These findings indicated that circ_0072309 could constitute a predictive biomarker and potential treatment strategy for NSCLC diagnosis and therapy.</p></sec></body><back><sec id="sec5" sec-type="COI-statement"><title>Competing Interests</title><p>The authors declare that there are no competing interests associated with the manuscript.</p></sec><sec id="sec6" sec-type="funding"><title>Funding</title><p>This work was supported by the Jiangmen Science and Technology Bureau.</p></sec><sec id="sec7" sec-type="author-contrib"><title>Author Contribution</title><p>Zheng Wang conceived and designed the present study. Wenguang Pang was responsible for doing the main experimental procedures and wrote the original manuscript. Fengliu Huang and Xin Zhang were responsible for validation. Min Ye and Yanming Huang were involved in extracting data. Xiufang Huang, Jingzhuo Pang and Chengjie Cai managed the analysis and undertook the statistical analysis. All authors have read and approved the final manuscript.</p></sec><glossary><title>Abbreviations</title><def-list list-content="abbreviations"><def-item><term id="G1">CCK-8</term><def><p>cell counting kit 8</p></def></def-item><def-item><term id="G2">circRNA</term><def><p>circular RNA</p></def></def-item><def-item><term id="G3">DMEM</term><def><p>Dulbecco&#x02019;s modified Eagle&#x02019;s medium</p></def></def-item><def-item><term id="G4">FBS</term><def><p>fetal bovine serum</p></def></def-item><def-item><term id="G5">FOXO3</term><def><p>forkhead box O3</p></def></def-item><def-item><term id="G6">GAPDH</term><def><p>glyceraldehyde-3-phosphate dehydrogenase</p></def></def-item><def-item><term id="G7">GEO</term><def><p>gene Expression Omnibus</p></def></def-item><def-item><term id="G8">HBE</term><def><p>human bronchial epithelial</p></def></def-item><def-item><term id="G9">NSCLC</term><def><p>non-small cell lung cancer</p></def></def-item><def-item><term id="G10">qRT-PCR</term><def><p>quantitative real-time PCR</p></def></def-item><def-item><term id="G11">TWIST1</term><def><p>twist homolog 1</p></def></def-item><def-item><term id="G12">VANGL1</term><def><p>Vang-Like 1</p></def></def-item></def-list></glossary><ref-list id="ref1"><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Witayateeraporn</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Arunrungvichian</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Pothongsrisit</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Doungchawee</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Vajragupta</surname><given-names>O.</given-names></name> and <name name-style="western"><surname>Pongrakhananon</surname><given-names>V.</given-names></name></person-group> (<year>2019</year>) <article-title>alpha7-Nicotinic acetylcholine receptor antagonist QND7 suppresses non-small cell lung cancer cell proliferation and migration via inhibition of Akt/mTOR signaling</article-title>. <source>Biochem. Biophys. Res. Commun.</source>
<volume>521</volume>, <fpage>997</fpage>&#x02013;<lpage>983</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbrc.2019.11.018</pub-id><?supplied-pmid 31727368?><pub-id pub-id-type="pmid">31727364</pub-id></mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Du</surname><given-names>Q.</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name> and <name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name></person-group> (<year>2019</year>) <article-title>The circRNA circP4HB promotes NSCLC aggressiveness and metastasis by sponging miR-133a-5p</article-title>. <source>Biochem. Biophys. Res. Commun.</source>
<volume>513</volume>, <fpage>904</fpage>&#x02013;<lpage>911</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbrc.2019.04.108</pub-id><?supplied-pmid 31005252?><pub-id pub-id-type="pmid">31005252</pub-id></mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Yan</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Shi</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Shi</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Duan</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Fan</surname><given-names>Q.</given-names></name><etal>et al</etal>.</person-group> (<year>2019</year>) <article-title>Expression of estrogen receptor beta and overall survival in non-small cell lung cancer patients: Protocol for a systematic review and meta-analysis of cohort studies</article-title>. <source>Medicine (Baltimore)</source>
<volume>98</volume>, <fpage>e17559</fpage>
<pub-id pub-id-type="doi">10.1097/MD.0000000000017559</pub-id><?supplied-pmid 31651857?><pub-id pub-id-type="pmid">31651857</pub-id></mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meng</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Feng</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Tang</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>P.</given-names></name><etal>et al</etal>.</person-group> (<year>2017</year>) <article-title>CircRNA: functions and properties of a novel potential biomarker for cancer</article-title>. <source>Mol. Cancer</source>
<volume>16</volume>, <fpage>94</fpage>
<pub-id pub-id-type="doi">10.1186/s12943-017-0663-2</pub-id><?supplied-pmid 28535767?><pub-id pub-id-type="pmid">28535767</pub-id></mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>D.</given-names></name> and <name name-style="western"><surname>Wilusz</surname><given-names>J.E.</given-names></name></person-group> (<year>2014</year>) <article-title>Short intronic repeat sequences facilitate circular RNA production</article-title>. <source>Genes Dev.</source>
<volume>28</volume>, <fpage>2233</fpage>&#x02013;<lpage>2247</lpage>
<pub-id pub-id-type="doi">10.1101/gad.251926.114</pub-id><?supplied-pmid 25281217?><pub-id pub-id-type="pmid">25281217</pub-id></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tong</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>H.</given-names></name> and <name name-style="western"><surname>Xiao</surname><given-names>J.</given-names></name></person-group> (<year>2019</year>) <article-title>CircZNF609/miR-134-5p/BTG-2 axis regulates proliferation and migration of glioma cell</article-title>. <source>J. Pharm. Pharmacol.</source>
<pub-id pub-id-type="doi">10.1111/jphp.13188</pub-id><?supplied-pmid 31721211?><pub-id pub-id-type="pmid">31721211</pub-id></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dong</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Ji</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>T.</given-names></name><etal>et al</etal>.</person-group> (<year>2019</year>) <article-title>The circular RNA-NRIP1 plays oncogenic roles by targeting microRNA-505 in the renal carcinoma cell lines</article-title>. <source>J. Cell. Biochem.</source>
<volume>121</volume>, <fpage>2236</fpage>&#x02013;<lpage>2246</lpage>
<pub-id pub-id-type="doi">10.1002/jcb.29446</pub-id><pub-id pub-id-type="pmid">31692056</pub-id></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Tang</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><etal>et al</etal>.</person-group> (<year>2019</year>) <article-title>Circular RNA hsa_circ_0030018 acts as a sponge of miR-599 to aggravate esophageal carcinoma progression by regulating ENAH expression</article-title>. <source>J. Cell. Biochem.</source>
<pub-id pub-id-type="doi">10.1002/jcb.29507</pub-id></mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name> and <name name-style="western"><surname>Shen</surname><given-names>M.</given-names></name></person-group> (<year>2019</year>) <article-title>Circular RNA hsa_circ_103809 suppresses hepatocellular carcinoma proliferation and invasion by sponging miR-620</article-title>. <source>Eur. Rev. Med. Pharmacol. Sci.</source>
<volume>23</volume>, <fpage>555</fpage>&#x02013;<lpage>566</lpage>
<?supplied-pmid 30720163?><pub-id pub-id-type="pmid">30720163</pub-id></mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>Q.</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>Q.Y.</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>Y.</given-names></name> and <name name-style="western"><surname>Wu</surname><given-names>S.</given-names></name></person-group> (<year>2019</year>) <article-title>High-throughput data reveals novel circular RNAs via competitive endogenous RNA networks associated with human intracranial aneurysms</article-title>. <source>Med. Sci. Monit.</source>
<volume>25</volume>, <fpage>4819</fpage>&#x02013;<lpage>4830</lpage>
<pub-id pub-id-type="doi">10.12659/MSM.917081</pub-id><?supplied-pmid 31254341?><pub-id pub-id-type="pmid">31254341</pub-id></mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Ruan</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Shen</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>T.</given-names></name> and <name name-style="western"><surname>Xiao</surname><given-names>B.</given-names></name></person-group> (<year>2019</year>) <article-title>Tumor-suppressive circular RNAs: Mechanisms underlying their suppression of tumor occurrence and use as therapeutic targets</article-title>. <source>Cancer Sci.</source>
<volume>110</volume>, <fpage> 3630</fpage>&#x02013;<lpage>3638</lpage>
<pub-id pub-id-type="doi">10.1111/cas.14211</pub-id><pub-id pub-id-type="pmid">31599076</pub-id></mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Zheng</surname><given-names>M.</given-names></name> and <name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name></person-group> (<year>2019</year>) <article-title>Circular RNA hsa_circ_0072309 inhibits proliferation and invasion of breast cancer cells via targeting miR-492</article-title>. <source>Cancer Manag. Res.</source>
<volume>11</volume>, <fpage>1033</fpage>&#x02013;<lpage>1041</lpage>
<pub-id pub-id-type="doi">10.2147/CMAR.S186857</pub-id><?supplied-pmid 30774431?><pub-id pub-id-type="pmid">30774431</pub-id></mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Shao</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name> and <name name-style="western"><surname>Cao</surname><given-names>Y.</given-names></name></person-group> (<year>2019</year>) <article-title>The circular RNA hsa-circ-0072309 plays anti-tumour roles by sponging miR-100 through the deactivation of PI3K/AKT and mTOR pathways in the renal carcinoma cell lines</article-title>. <source>Artif. Cells Nanomed. Biotechnol.</source>
<volume>47</volume>, <fpage>3638</fpage>&#x02013;<lpage>3648</lpage>
<pub-id pub-id-type="doi">10.1080/21691401.2019.1657873</pub-id><?supplied-pmid 31456425?><pub-id pub-id-type="pmid">31456425</pub-id></mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Lu</surname><given-names>H.</given-names></name> and <name name-style="western"><surname>Qin</surname><given-names>Y.</given-names></name></person-group> (<year>2019</year>) <article-title>Circular RNA SMARCA5 inhibits the proliferation, migration, and invasion of non-small cell lung cancer by miR-19b-3p/HOXA9 axis</article-title>. <source>Onco Targets Ther.</source>
<volume>12</volume>, <fpage>7055</fpage>&#x02013;<lpage>7065</lpage>
<pub-id pub-id-type="doi">10.2147/OTT.S216320</pub-id><?supplied-pmid 31564891?><pub-id pub-id-type="pmid">31564891</pub-id></mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qian</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>Y.Q.</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>Z.H.</given-names></name>, <name name-style="western"><surname>Zhangsun</surname><given-names>D.T.</given-names></name> and <name name-style="western"><surname>Luo</surname><given-names>S.L.</given-names></name></person-group> (<year>2019</year>) <article-title>Identification of nicotinic acetylcholine receptor subunits in different lung cancer cell lines and the inhibitory effect of alpha-conotoxin TxID on lung cancer cell growth</article-title>. <source>Eur. J. Pharmacol.</source>
<volume>865</volume>, <fpage>172674</fpage>
<pub-id pub-id-type="doi">10.1016/j.ejphar.2019.172674</pub-id><?supplied-pmid 31634461?><pub-id pub-id-type="pmid">31634461</pub-id></mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>A.</given-names></name></person-group> (<year>2011</year>) <article-title>Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC</article-title>. <source>Lung Cancer</source>
<volume>71</volume>, <fpage>3</fpage>&#x02013;<lpage>10</lpage>
<pub-id pub-id-type="doi">10.1016/j.lungcan.2010.08.022</pub-id><?supplied-pmid 20951465?><pub-id pub-id-type="pmid">20951465</pub-id></mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Fan</surname><given-names>Y.</given-names></name> and <name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name></person-group> (<year>2019</year>) <article-title>Antiproliferative activity of carnosic acid is mediated via inhibition of cell migration and invasion, and suppression of phosphatidylinositol 3-kinases (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling pathway</article-title>. <source>Med. Sci. Monit.</source>
<volume>25</volume>, <fpage>7864</fpage>&#x02013;<lpage>7871</lpage>
<pub-id pub-id-type="doi">10.12659/MSM.917735</pub-id><?supplied-pmid 31631173?><pub-id pub-id-type="pmid">31631173</pub-id></mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Jing</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>An</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Yan</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>H.</given-names></name><etal>et al</etal>.</person-group> (<year>2019</year>) <article-title>Prognostic significance of peripheral CD8+CD28+ and CD8+CD28- T cells in advanced non-small cell lung cancer patients treated with chemo(radio)therapy</article-title>. <source>J. Transl. Med.</source>
<volume>17</volume>, <fpage>344</fpage>
<pub-id pub-id-type="doi">10.1186/s12967-019-2097-7</pub-id><?supplied-pmid 31623615?><pub-id pub-id-type="pmid">31623615</pub-id></mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Han</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Ren</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Ren</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name> and <name name-style="western"><surname>Sun</surname><given-names>Z.</given-names></name></person-group> (<year>2019</year>) <article-title>Circular RNA HIPK3 induces cell proliferation and inhibits apoptosis in non-small cell lung cancer through sponging miR-149</article-title>. <source>Cancer Biol. Ther.</source>
<volume>21</volume>, <fpage>113</fpage>&#x02013;<lpage>121</lpage>
<pub-id pub-id-type="doi">10.1080/15384047.2019.1669995</pub-id><pub-id pub-id-type="pmid">31597523</pub-id></mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y.F.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name> and <name name-style="western"><surname>Yu</surname><given-names>L.</given-names></name></person-group> (<year>2019</year>) <article-title>Circular RNAs regulate cancer onset and progression via Wnt/beta-catenin signaling pathway</article-title>. <source>Yonsei Med. J.</source>
<volume>60</volume>, <fpage>1117</fpage>&#x02013;<lpage>1128</lpage>
<pub-id pub-id-type="doi">10.3349/ymj.2019.60.12.1117</pub-id><?supplied-pmid 31769242?><pub-id pub-id-type="pmid">31769242</pub-id></mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Fan</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Fang</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>T.</given-names></name><etal>et al</etal>.</person-group> (<year>2019</year>) <article-title>CircRNAs in cancer metabolism: a review</article-title>. <source>J. Hematol. Oncol.</source>
<volume>12</volume>, <fpage>90</fpage>
<pub-id pub-id-type="doi">10.1186/s13045-019-0776-8</pub-id><?supplied-pmid 31484561?><pub-id pub-id-type="pmid">31484561</pub-id></mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Qian</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Fang</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>B.</given-names></name><etal>et al</etal>.</person-group> (<year>2019</year>) <article-title>Silencing circular RNA VANGL1 inhibits progression of bladder cancer by regulating miR-1184/IGFBP2 axis</article-title>. <source>Cancer Med.</source>
<volume>9</volume>, <fpage> 700</fpage>&#x02013;<lpage>710</lpage>
<pub-id pub-id-type="doi">10.1002/cam4.2650</pub-id><pub-id pub-id-type="pmid">31758655</pub-id></mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X.Y.</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>Y.R.</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>J.H.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Guo</surname><given-names>H.H.</given-names></name> and <name name-style="western"><surname>Ma</surname><given-names>H.P.</given-names></name></person-group> (<year>2019</year>) <article-title>Enhanced expression of circular RNA hsa_circ_000984 promotes cells proliferation and metastasis in non-small cell lung cancer by modulating Wnt/beta-catenin pathway</article-title>. <source>Eur. Rev. Med. Pharmacol. Sci.</source>
<volume>23</volume>, <fpage>3366</fpage>&#x02013;<lpage>3374</lpage>
<?supplied-pmid 31081091?><pub-id pub-id-type="pmid">31081091</pub-id></mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kong</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Wan</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Lu</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><etal>et al</etal>.</person-group> (<year>2019</year>) <article-title>Circular RNA circFOXO3 promotes prostate cancer progression through sponging miR-29a-3p</article-title>. <source>J. Cell. Mol. Med.</source>
<volume>24</volume>, <fpage>799</fpage>&#x02013;<lpage>813</lpage>
<pub-id pub-id-type="doi">10.1111/jcmm.14791</pub-id><pub-id pub-id-type="pmid">31733095</pub-id></mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Mao</surname><given-names>X.W.</given-names></name> and <name name-style="western"><surname>Jiang</surname><given-names>L.Y.</given-names></name></person-group> (<year>2018</year>) <article-title>Circular RNA ciRS-7 correlates with advance disease and poor prognosis, and its down-regulation inhibits cells proliferation while induces cells apoptosis in non-small cell lung cancer</article-title>. <source>Eur. Rev. Med. Pharmacol. Sci.</source>
<volume>22</volume>, <fpage>8712</fpage>&#x02013;<lpage>8721</lpage>
<?supplied-pmid 30575911?><pub-id pub-id-type="pmid">30575911</pub-id></mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name> and <name name-style="western"><surname>Li</surname><given-names>H.</given-names></name></person-group> (<year>2018</year>) <article-title>CircRNA circ_0067934 silencing inhibits the proliferation, migration and invasion of NSCLC cells and correlates with unfavorable prognosis in NSCLC</article-title>. <source>Eur. Rev. Med. Pharmacol. Sci.</source>
<volume>22</volume>, <fpage>3053</fpage>&#x02013;<lpage>3060</lpage>
<?supplied-pmid 29863250?><pub-id pub-id-type="pmid">29863250</pub-id></mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Su</surname><given-names>Q.</given-names></name> and <name name-style="western"><surname>Lv</surname><given-names>X.</given-names></name></person-group> (<year>2019</year>) <article-title>Revealing new landscape of cardiovascular disease through circular RNA-miRNA-mRNA axis</article-title>. <source>Genomics</source>
<volume>112</volume>, <fpage>1680</fpage>&#x02013;<lpage>1685</lpage>
<pub-id pub-id-type="doi">10.1016/j.ygeno.2019.10.006</pub-id><pub-id pub-id-type="pmid">31626900</pub-id></mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dong</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>He</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Peng</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Peng</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Shi</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><etal>et al</etal>.</person-group> (<year>2017</year>) <article-title>Circular RNAs in cancer: an emerging key player</article-title>. <source>J. Hematol. Oncol.</source>
<volume>10</volume>, <fpage>2</fpage>
<pub-id pub-id-type="doi">10.1186/s13045-016-0370-2</pub-id><?supplied-pmid 28049499?><pub-id pub-id-type="pmid">28049499</pub-id></mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maestro</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Dei Tos</surname><given-names>A.P.</given-names></name>, <name name-style="western"><surname>Hamamori</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Krasnokutsky</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Sartorelli</surname><given-names>V.</given-names></name>, <name name-style="western"><surname>Kedes</surname><given-names>L.</given-names></name><etal>et al</etal>.</person-group> (<year>1999</year>) <article-title>Twist is a potential oncogene that inhibits apoptosis</article-title>. <source>Genes Dev.</source>
<volume>13</volume>, <fpage>2207</fpage>&#x02013;<lpage>2217</lpage>
<pub-id pub-id-type="doi">10.1101/gad.13.17.2207</pub-id><?supplied-pmid 10485844?><pub-id pub-id-type="pmid">10485844</pub-id></mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nairismagi</surname><given-names>M.L.</given-names></name>, <name name-style="western"><surname>Vislovukh</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Meng</surname><given-names>Q.</given-names></name>, <name name-style="western"><surname>Kratassiouk</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Beldiman</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Petretich</surname><given-names>M.</given-names></name><etal>et al</etal>.</person-group> (<year>2012</year>) <article-title>Translational control of TWIST1 expression in MCF-10A cell lines recapitulating breast cancer progression</article-title>. <source>Oncogene</source>
<volume>31</volume>, <fpage>4960</fpage>&#x02013;<lpage>4966</lpage>
<pub-id pub-id-type="doi">10.1038/onc.2011.650</pub-id><?supplied-pmid 22266852?><pub-id pub-id-type="pmid">22266852</pub-id></mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Almog</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Ma</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Schwager</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Brinkmann</surname><given-names>B.G.</given-names></name>, <name name-style="western"><surname>Beheshti</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Vajkoczy</surname><given-names>P.</given-names></name><etal>et al</etal>.</person-group> (<year>2012</year>) <article-title>Consensus micro RNAs governing the switch of dormant tumors to the fast-growing angiogenic phenotype</article-title>. <source>PLoS ONE</source>
<volume>7</volume>, <fpage>e44001</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0044001</pub-id><?supplied-pmid 22952847?><pub-id pub-id-type="pmid">22952847</pub-id></mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramraj</surname><given-names>S.K.</given-names></name>, <name name-style="western"><surname>Aravindan</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Somasundaram</surname><given-names>D.B.</given-names></name>, <name name-style="western"><surname>Herman</surname><given-names>T.S.</given-names></name>, <name name-style="western"><surname>Natarajan</surname><given-names>M.</given-names></name> and <name name-style="western"><surname>Aravindan</surname><given-names>N.</given-names></name></person-group> (<year>2016</year>) <article-title>Serum-circulating miRNAs predict neuroblastoma progression in mouse model of high-risk metastatic disease</article-title>. <source>Oncotarget</source>
<volume>7</volume>, <fpage>18605</fpage>&#x02013;<lpage>18619</lpage>
<pub-id pub-id-type="doi">10.18632/oncotarget.7615</pub-id><?supplied-pmid 26921195?><pub-id pub-id-type="pmid">26921195</pub-id></mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>L.Y.</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>P.</given-names></name><etal>et al</etal>.</person-group> (<year>2019</year>) <article-title>Bioinformatics analysis identifies microRNAs and target genes associated with prognosis in patients with melanoma</article-title>. <source>Med. Sci. Monit.</source>
<volume>25</volume>, <fpage>7784</fpage>&#x02013;<lpage>7794</lpage>
<pub-id pub-id-type="doi">10.12659/MSM.917082</pub-id><?supplied-pmid 31621692?><pub-id pub-id-type="pmid">31621692</pub-id></mixed-citation></ref></ref-list></back></article>